As part of their series focusing on medicines in Australia, Research Review have completed a product review of the use of dapagliflozin in patients with chronic kidney disease, heart failure and type 2 diabetes.
This publication focuses on the efficacy and safety of dapagliflozin and provides commentary from a multi-disciplinary team of specialists including Associate Professor John Amerena, Professor Carol Pollock and Professor Jonathan Shaw.